HB1102 — INS CD-CANCER SCREENINGS
Last action — House Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee
-
1Introduced
-
2In Committee
-
3Passed House
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill has been introduced in the House. Introduced January 03, 2025. It must pass committee before a floor vote.
Next likely step: a committee referral and hearing.
Prognosis
Where this bill stands today.
Odds of enactment
LowHow often bills like it became law.
Not enough signal yet to read this bill's trajectory — we surface a likelihood only once there's real movement (stage, sponsorship, committee, or votes) to point to.
Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.
Summary
Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
Bill Text
We don't have the full text on file for this bill yet.
Read HB1102 on the official Illinois source →Action History
-
House Committee Amendment No. 1 Rule 19(c) / Re-referred to Rules Committee
-
Rule 19(a) / Re-referred to Rules Committee
-
House Committee Amendment No. 1 Rules Refers to Insurance Committee
-
House Committee Amendment No. 1 Referred to Rules Committee
-
House Committee Amendment No. 1 Filed with Clerk by Rep. Jed Davis
-
To Insurance Main Subcommittee
-
Assigned to Insurance Committee
-
Referred to Rules Committee
-
First Reading
-
Prefiled with Clerk by Rep. Jed Davis
Sponsors
- Jed Davis · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 182 not signed on
Sponsors (1)
- Jed Davis Republican
Co-sponsors (0)
None.
Not signed on (182)
182 members have not signed on to this bill.
Show all 182 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HB1102 do?
- Amends the Illinois Insurance Code. In a provision concerning coverage of certain cancer screenings, adds having a high level of CA-125, as indicated by a blood test screening, to the definition of "at risk for ovarian cancer". Provides that "surveillance tests for ovarian cancer" means all medically viable methods for the detection and diagnosis of ovarian cancer, including, but not limited to, ultrasounds, magnetic resonance imagings (MRIs), x-rays, computed tomography (CT) scans, and CA-125 blood test screenings (instead of an annual screening using (i) CA-125 serum tumor marker testing, (ii) transvaginal ultrasound, (iii) pelvic examination). Effective January 1, 2027.
- Who sponsors HB1102 ?
- HB1102 is sponsored by Jed Davis (Republican).
- What is the current status of HB1102 ?
- This bill has been introduced in the House. Introduced January 03, 2025. It must pass committee before a floor vote.
- Where can I track HB1102 ?
- Track HB1102 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HB1102
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HB1102
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →